SCHEMBL2279810

SCHEMBL2279810

COC(=O)CSCc1cccc(C=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
KMT2A Q03164 2/20 0.45
RAB9A P51151 4/20 0.42
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
FFAR1 O14842 1/20 0.40
MAPK1 P28482 1/20 0.40
POLB P06746 1/20 0.40
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
UNG P13051 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1124720 0.81 SLC7A5 (0.56) CYP4F2CYP4A11RAB9AMAOAMAOB
SCHEMBL4396667 0.80 CYP1A2 (0.54) CYP1A2KMT2ARAB9AFFAR1MAPK1
SCHEMBL2210286 0.79 CYP1A2 (0.52) CYP1A2KMT2ARAB9AFFAR1MAPK1
SCHEMBL3913913 0.79 CYP1A2 (0.52) CYP1A2KMT2ARAB9AFFAR1MAPK1
SCHEMBL698078 0.79 CYP4F2 (0.55) CYP4F2CYP4A11RAB9AMAOAMAOB
SCHEMBL560042 0.77 MAPK1 (0.59) CYP1A2RAB9AFFAR1MAPK1NPC1
SCHEMBL3286710 0.75 UNG (0.43) CYP1A2RAB9AMAOAMAOBFFAR1
SCHEMBL4396952 0.74 CYP1A2 (0.58) CYP1A2KMT2ARAB9AFFAR1MAPK1
SCHEMBL10224882 0.74 MAOA (0.45) CYP4F2CYP4A11RAB9AMAOAMAOB
SCHEMBL1798827 0.73 SLC7A5 (0.51) CYP4F2CYP4A11KMT2ARAB9AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7691883-B2 Cinnamoyl compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-06 US disclosed
US-20070265228-A1 Cinnamoyl compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-11-15 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671961-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 CYP1A2 2505/4885CYP4F2 1392/4885CYP4A11 2078/4885
US-20070265228-A1 Cinnamoyl compound and use of the same NPC1, CES2, CYP51A1 CYP1A2 367/4885CYP4F2 405/4885CYP4A11 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.